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Abstract
Background: The clinical use of mefloquine (MQ) has declined due to dose-related neurological events. Next
generation quinoline methanols (NGQMs) that do not accumulate in the central nervous system (CNS) to the same
extent may have utility. In this study, CNS levels of NGQMs relative to MQ were measured and an early lead
chemotype was identified for further optimization.
Experimental design: The plasma and brain levels of MQ and twenty five, 4-position modified NGQMs were
determined using LCMS/MS at 5 min, 1, 6 and 24 h after IV administration (5 mg/kg) to male FVB mice. Fraction
unbound in brain tissue homogenate was assessed in vitro using equilibrium dialysis and this was then used to
calculate brain-unbound concentration from the measured brain total concentration. A five-fold reduction CNS
levels relative to mefloquine was considered acceptable. Additional pharmacological properties such as
permeability and potency were determined.
Results: The maximum brain (whole/free) concentrations of MQ were 1807/4.9 ng/g. Maximum whole brain
concentrations of NGQMs were 23 - 21546 ng/g. Maximum free brain concentrations were 0.5 to 267 ng/g. Seven
(28%) and two (8%) compounds exhibited acceptable whole and free brain concentrations, respectively.
Optimization of maximum free brain levels, IC90s (as a measure or potency) and residual plasma concentrations at
24 h (as a surrogate for half-life) in the same molecule may be feasible since they were not correlated. Diamine
quinoline methanols were the most promising lead compounds.
Conclusion: Reduction of CNS levels of NGQMs relative to mefloquine may be feasible. Optimization of this
property together with potency and long half-life may be feasible amongst diamine quinoline methanols.
Background
The Walter Reed Army Institute of Research and colla-
borators are attempting to identify next generation qui-
noline methanols for intermittent preventive treatment
(IPT) of malaria. IPT is the prevention of morbidity or
mortality due to malaria through the intermittent admin-
istration of a single dose treatment of a drug at full thera-
peutic doses to asymptomatic, otherwise healthy infants
(IPTi), pregnant women (IPTp) and travelers (IPTt)
[1-3]. Drugs for IPTx indications and prophylaxis should
ideally exhibit a long half-life, be very well-tolerated and
safe in pregnancy. Mefloquine exhibits two of these char-
acteristics, but will likely not find use as an IPT drug
because of the adverse CNS events observed at the treat-
ment level doses [4] that may be required for IPT. How-
ever, this would presumably not be an issue for next
generation analogs of mefloquine without such a liability.
Mefloquine accumulates in the CNS and has multiple
CNS targets (see discussion in earlier papers [5,6]). The
goal is to identify a lead compound for IPT, based on a
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CNS is substantially reduced. Such a compound should
have an improved CNS safety profile relative to
mefloquine.
In an earlier study, it was demonstrated that non-piperi-
dine quinoline methanols, in which the piperidine group
of mefloquine was replaced with a diamine side chain,
were metabolically stable, exhibited reasonable potency
against Plasmodium falciparum in vitro and were less
permeable across MDCK cell monolayers than their mon-
amine counterparts [7,8]. That study did not attempt to
address whether reductions in brain concentration relative
to mefloquine could be achieved in vivo. This was the goal
of the present study, in which approximately 25 com-
pounds from our original library were resynthesized, and
brain and plasma concentrations were measured over 24 h
in mice after i.v. dosing. Plasma concentrations were mea-
sured to generate a preliminary indication of half-life,
brain concentrations to assess potential exposure relative
to mefloquine, and IC90s to assess intrinsic activity against
P. falciparum.
The dose-limiting CNS side effects of mefloquine at the
full therapeutic doses required for IPT include dizziness,
incoordination, anxiety and sleeplessness [9]. These com-
m o ns i d ee f f e c t sa r el a r g e l ya b s e n ta tt h ew e e k l yd o s eo f
mefloquine, which is five-fold lower than the treatment
dose [10]. Therefore, assuming linearity of mefloquine
pharmacokinetics in humans, it makes sense that, assum-
ing no change in affinity for the putative CNS receptors
of mefloquine, a five-fold reduction in CNS total drug
levels would be the minimum requirement to reasonably
expect an improvement in the therapeutic index of a
NGQM delivering efficacy at blood exposure equivalent
to mefloquine. However, as reported elsewhere [7,8], the
lipophilicity of diamine quinoline methanols and other
early lead chemotypes is lower than mefloquine. Concei-
vably this might alter non-specific binding in the brain
leading to an increase in the free brain concentration of
the drug. Since we do not know the relevant clinical CNS
target(s) of mefloquine and the importance of the total
and free brain concentration in relation to adverse
effects, it is important that reduction relative to meflo-
quine be assessed with respect to both parameters.
Methods
Library synthesis and physicochemical properties
Racemic mefloquine and its (+) and (-) erythro enantio-
mers were obtained from the WRAIR chemical inven-
tory system. A sub-library of 25 next generation
quinoline methanols was synthesized as described in our
earlier papers [7,8]. Compounds were almost all rule of
5 (RO5) compliant [11] and designed to encompass the
widest feasible range of physiochemical properties (see
Table 1). All physiochemical properties were calculated
using ACD (Version 10, ACD Labs, Toronto, Canada)
except for LogD (pH 7.4) which was determined using
Pipeline Pilot. (Version 6.1, Accelrys, San Diego, Califor-
nia). These properties have been defined in detail else-
where [12], and numerically represent the size (MW),
lipophilicity (LogD and LogP), molecular flexibility
(FRBs) and H-bonding capacity (HBDs and HBAs) of a
compound, all of which impact biological properties
important in drug development. The importance of
these properties in drug discovery generally and to next
generation quinoline methanols more specifically is dis-
cussed elsewhere [8]. Given that the focus of this study
was on brain penetration, the sub-library of compounds
was selected such that a wide range of brain levels was
expected based on their physiochemical properties.
Animals, dosing and collection of samples
All in vivo studies were conducted in accordance with
protocols approved by the Victorian College of Phar-
macy, Animal Ethics Committee. Male, six week old
FVB mice were obtained from the Animals Resources
Center (Perth, Western Australia) and provided with
food and water ad libitum. Mice were administered a 50
μL bolus injection of mefloquine, its enantiomers or one
of twenty five quinoline methanol compounds by tail
vein injection (dosing solution concentration 2.8 mg/ml)
for a nominal dose of 5 mg/kg. The compounds were
prepared in 5% DMSO in 5% glucose solution buffered
to a pH of 3-5 using citrate or acetate as appropriate
based on an assessment of the lipophilicity and pKa of
the compound. At 5 min, 1 h, 6 h or 24 h post-dosing,
mice were anaesthetized with inhaled isoflurane (3%)
approximately 3-4 minutes prior to blood and brain har-
vest. Blood was collected by cardiac puncture from
groups of 2-3 mice and the whole brain was removed.
The whole brains were placed into preweighed polypro-
pylene vials and snap frozen prior to storage along with
the plasma samples at -20°C until analysis. On the day
of analysis, the whole brain was homogenized in three
parts of aqueous solution containing 0.1 M EDTA and
0.4 g/L KF (inhibitors of hydrolytic enzymes to reduce
Table 1 Ranges of physiochemical properties of quinoline
methanols investigated in this study
Parameter Range
MW 324-475
cLogD (PP) 1.0-5.2
cLogD (ACD) -2.3-3.1
PSA (Å
2) 36-104
LogP 0.4-3.7
# FRBs 3-11
# HBDs 1-5
# HBAs 3-7
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Page 2 of 11the potential for ex vivo tissue-mediated degradation of
the test compounds). Calibration standards were pre-
pared by spiking blank brain homogenate and blank
plasma with the test compound. Both samples and stan-
dards were processed by adding acetonitrile (to precipi-
tate proteins) and centrifuged to separate the
supernatant for analysis. An aliquot of the supernatant
from each brain homogenate and plasma samples were
analysed by UPLC/MS/MS on either a Quattro Premier
XE, a Quattro Ultima Pt or a Xevo XT Mass Spectro-
meter (Waters Corporation, USA).
Determination of unbound brain fractions by equilibrium
dialysis and free brain levels
The unbound fraction of each analog in mouse brain
homogenate was determined in vitro using equilibrium
dialysis according to methodology reported previously
[13]. In brief, a 96 well equilibrium dialysis apparatus
was used to determine the unbound fraction in brain
homogenate for each compound (HT Dialysis LLC,
Gales Ferry, CT). Membranes (12-14 kDA cut-off)
were conditioned in deionized water for 60 minutes,
followed by conditioning in 80:20 deionized water:etha-
nol for 20 minutes, and then rinsed in artificial cere-
brospinal fluid (CSF) before use. Mouse brain was
removed from the freezer and allowed to thaw on the
day of experiment. Thawed brain tissue was then
homogenized with artificial CSF to a final composition
of 1:2 brain:artificial CSF using a Covaris S2 (K Bios-
ciences, Hoddesdon, UK). Diluted brain homogenate
was then spiked with the test compound (10 ug/g), and
150 μL aliquots (n = 6 replicate determinations) loaded
into the 96-well equilibrium dialysis plate. Dialysis vs
artificial CSF (150 μL) was carried out for 5 hours in a
temperature controlled incubator at ca.3 7 ° C( B a r w o r l d
Scientific Ltd, UK) using an orbital microplate shaker
at 125 revolutions/minute (Barworld scientific Ltd,
UK). At the end of the incubation period, aliquots of
brain homogenate or artificial CSF were transferred to
micronic tubes (Micronic B.V., the Netherlands) and
the composition in each tube balanced with control
fluid, such that the volume of artificial CSF to brain
was the same. Sample extraction was performed by the
addition of 400 μL of acetonitrile containing an appro-
priate internal standard. Samples were allowed to mix
for 1 minute and then centrifuged at 3000 rpm in 96-
well blocks for 15 minutes (Allegra X12-R, Beckman
Coulter, USA). All samples were then analysed by
UPLC/MS/MS on a Quattro Premier XE Mass Spectro-
meter (Waters Corporation, USA). The unbound frac-
tion in brain was determined as the ratio of the peak
area in artificial CSF to that in brain, with correction
for dilution factor according to eq.1 [14].
Undiluted fu =
1/D

1/fu,apparent

− 1

+1 / D
(1)
where D = dilution factor in brain homogenate and fu,
apparent is the measured free fraction of diluted brain
homogenate.
Free brain levels were determined from measured
whole brain concentrations and the undiluted fu as fol-
lows:
Free Brain Concentration = Whole Brain Concentration × Undiluted fu (2)
Determination of apparent permeability across MDCK cell
layers
Permeability was determined by Absorption Systems
(Exton, PA). MDR1-MDCK cell monolayers were grown
to confluence on collagen-coated, microporous, polycar-
bonate membranes in 12-well Costar Transwell plates.
Data were considered valid for a specific assay plate if
TEER values were < 1400 Ω.cm
2,t h eP app of propanolol
was between 10-30 × 10
-6 cm/s and the Papp of atenolol
was < 0.5 × 10
-6 cm/s. The permeability assay buffer
was Hanks Balanced Salt Solution containing 10 mM
HEPES and 15 mM glucose at a pH of 7.4. A known p-
glycoprotein inhibitor, cyclosporin A (CSA), was also
added to the assay buffer at 10 μM. This was omitted
for amphoteric compounds. Bovine serum albumin (1%)
was added to the receiver well. The dosing solution con-
centrations of the test compounds were 5.0 μMi nt h e
assay buffer. All cell monolayers were first pre-incubated
for 30 minutes with assay buffer. After 30 minutes, the
buffer was removed, replaced with fresh buffer, and time
was recorded as 0. The addition of BSA, pre-incubation,
and use of a longer incubation time were employed to
mitigate potential low recovery or permeability that is
sometimes observed for lipophilic or ‘sticky’ compounds.
Cell monolayers were dosed on the apical side (A-to-B)
or basolateral side (B-to-A) and incubated at 37°C with
5% CO2 in a humidified incubator. After two hours, ali-
quots were taken from the receiver chambers. Samples
were taken from the donor chamber at 0 and 2 hours.
Each determination was performed in duplicate. The
lucifer yellow flux was also measured for each mono-
layer to assess monolayer integrity during the flux per-
iod. All samples were assayed by LC/MS/MS using
electrospray ionization.
Apparent permeability in the apical (A-B direction),
PappA-B, and percent recovery are reported in the sup-
plementary Information. Apparent permeability is a
measure of the rate of transport across the cell mono-
layer. Percent recovery refers to the amount of com-
pound recoverable at the end of the assay. Low recovery
Dow et al. Malaria Journal 2011, 10:150
http://www.malariajournal.com/content/10/1/150
Page 3 of 11m a yi n d i c a t en o n - s p e c i f i cb i n d i n gt oa s s a yp l a t e s ,
instability or accumulation in the cell pellet. In the case
of mefloquine, relatively low recovery is likely a conse-
quence of accumulation in cell membranes [15,16]
rather than non-specific binding.
The apparent permeability, Papp, and percent recovery
were calculated as follows:
Papp =

dCr/dt

× Vr/ (A × C0) (3)
Percent Recovery = 100 ×

Vr × Crﬁnal

+

Vd × Cd
ﬁnal

/(Vd × CN) (4)
where,
dCr/dt is the slope of the cumulative concentration in
the receiver compartment versus time in μMs
-1.
Vr is the volume of the receiver compartment in cm
3.
Vd is the volume of the donor compartment in cm
3.
A is the area of the cell monolayer (1.13 cm
2 for 12-
well Transwell).
C0 is the measured concentration of the donor cham-
ber at time 0 in μM.
CN is the nominal concentration of the dosing solu-
tion in μM.
Cr
final is the cumulative receiver concentration in μM
at the end of the incubation period.
Cd
final is the concentration of the donor in μMa tt h e
end of the incubation period.
Plasmodium falciparum susceptibility assays
The in vitro activities of quinoline methanols against
P. falciparum strains W2, D6, TM91C235, and
TM90C2A were evaluated using the traditional labeled
hypoxanthine assay of Desjardins et al [17] as modified
by Milhous et al [18]. These four P. falciparum strains
were selected since they have various levels of resistance
to conventional anti-malarials. W2 is chloroquine resis-
tant and mefloquine sensitive, D6 is chloroquine sensi-
tive but naturally less susceptible to mefloquine,
TM91C235 is resistant to mefloquine, chloroquine, and
pyrimethamine as is TM90C2A, however this latter
parasite is a two pfmdr1 copy strain (pfmdr1 amplifica-
tion has been associated with clinical mefloquine resis-
tance). Mefloquine is routinely screened in these assays
to ensure the validity. Historical values for mefloquine
against all the strains are reported elsewhere [8]. The
f o c u so ft h i ss t u d yw a st h em e floquine-sensitive strain
W2, however values for the other strains for all
the compounds are reported in the Supplementary
Information.
Data analysis
Prism graphing software was used to graph key datasets
in order to facilitate visual inspection for possible corre-
lations amongst parameters of interest followed by
statistical confirmation if needed. For graphical analysis
of IC90 data, IC90s were assumed to be equivalent to
the maximum concentrations tested where they were
insufficiently potent to be determined. Our brain uptake
studies yielded plasma concentration data for four time
points. This was insufficient for the purposes of deter-
mining half-lives in most instances. As a surrogate for
half-life, we determined the % residual plasma concen-
trations at 24 h versus concentrations at 5 min. Where
the measured plasma concentration was below the ana-
lytical lower limit of quantitation (LLQ), an arbitrary
value of 1 ng/ml was assigned for the purposes of analy-
sis. For analysis of MDCK permeability data versus max-
imum brain concentration, we did not adjust Papp
values on the basis of % recovery. However, percent
recovery values are included in the Supplementary
Information. The probability of a diamine exhibiting the
desired free brain concentration, IC90s and residual
plasma concentration was calculated by multiplying the
marginal probabilities of each of these events since they
appeared to be independent. The +/- 95% confidence
limits for the probability estimate was calculated using
the formula: +/- 95% CIs = 1.96*SQRT(P*(1-P)/n) where
P is probability of success and SQRT is the square root
of the result of the function in brackets.
Results
Twenty-five quinoline methanols were successfully
resynthesized or obtained from the WRAIR chemical
inventory system. Their structures are depicted in
Figure 1. Physicochemical properties, in vitro suscept-
ibility data, brain tissue binding data, brain and plasma
concentrations and MDCK screening data are summar-
ized in Additional file 1. The range of physicochemical
properties encompassed by the mini-library of com-
pounds is summarized in Table 1.
The maximum whole and free brain concentrations of
the quinoline methanols are summarized in Figures 2A
and 2B, respectively. The maximum whole and free
brain concentrations of racemic mefloquine were 1807
and 4.9 ng/g. For the (+) and (-) mefloquine enantio-
mers, these values were (whole/free) 1159/2.5 and 2249/
5.2 ng/g, respectively. The lowest whole brain concen-
tration was 23 ng/g (WR318470) and the lowest free
brain concentration was 0.45 ng/g (WR319535). Of the
25 novel compounds, 7 (28%) and 2 (8%) passed the
minimum acceptable five-fold reduction in whole and
free brain levels, respectively.
Pharmacological data for four important parameters
were examined for evidence of possible correlations in
order to justify assumptions regarding probability esti-
mates and to assess the feasibility of the optimization of
desirable traits in a single molecule. There was no evi-
dence of correlations amongst the following parameters:
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Page 4 of 11residual plasma concentrations at 24 h, maximum free
brain concentration and IC90s (Figures 3A-C). This sug-
gests that (i) their probability distributions may be inde-
pendent and (ii) they may be optimizable in the same
molecule. There was an apparent linear relationship
evident between maximum whole and free brain con-
centrations (Figure 3D), that was confirmed mathemati-
cally (r
2 = 0.89, P < 0.0001, linear regression). This
suggests that these variables are not independent and
that 89% of the variability in free brain concentrations
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Page 5 of 11can be explained by variability in whole brain concentra-
tions alone. There was no qualitative evidence of a sim-
ple linear correlation between IC90 and maximum
whole brain concentration (Figure 3E). However, the
lack of data in the lower left quadrant suggests more
caution in making the assumption of independence
between these two variables. There was no evidence of
correlation between residual drug concentrations and
maximum whole brain concentration (Figure 3F).
One of the most promising compounds was WR319535
(Figures 1, 2 and 4). This compound exhibited maximum
whole and free brain concentrations of 145 and 0.45 ng/g,
respectively. Significant drug levels remained at 24 h post-
dosing (Figure 4) compared to many of the other com-
pounds investigated (Supplementary Information) which
may imply a long half-life. Unfortunately, the compound
exhibited only modest potency. Four related diamine qui-
noline methanols (Figure 5) were also evaluated. When
these were considered together, 1 in 5 exhibited appropri-
ate potency, 1 in 5 exhibited appropriate whole brain
levels, and 1 in 5 exhibited appropriate free brain levels
relative to mefloquine. All of these compounds were
represented in the group of 9 non-piperidine compounds
with residual plasma concentrations > 1% of the observed
maximum value. This suggests they represent the sub-che-
motype with the greatest propensity for a long half-life.
The probability (+/- 95% confidence intervals) of such a
molecule exhibiting the desired free brain levels, potency
and residual plasma concentrations was estimated to be 4
(0-21)% (Figure 5).
The apparent permeability (A-B) of quinoline metha-
nols was used to categorize them as having either higher
(if Papp was > 7.4 × 10
-6 cm/s) or lower (if Papp was <
7.4 × 10
-6 cm/s) maximum brain concentrations than
mefloquine in vivo (Table 2). Compounds with apparent
permeability values of < 7.4 × 10
-6 cm/s exhibited lower
brain concentrations than mefloquine in vivo in 100% of
cases. Compounds with apparent permeability > 7.4 ×
10
-6 cm/s exhibited maximum brain concentrations
higher than mefloquine in 71% of cases (Table 2). Thus,
is it is likely that an MDCK permeability acceptability
threshold of < 7.4 × 10
-6 cm/s would exclude most
future compounds for which maximum brain concentra-
tions are higher than mefloquine.
Discussion
The focus of the WRAIR discovery program with next
generation quinoline methanols has been to reduce par-
titioning into the CNS since the relevant clinical target
or targets of mefloquine adverse events are not known
[19]. The incidence of the most common adverse CNS
effects of mefloquine is reduced substantially when the
dose is lowered five-fold from the treatment to the
weekly prophylaxis level. Presumably this is also asso-
ciated with a five-fold decline in CNS levels as well.
Consequently, at least a five-fold reduction in whole and
free brain levels relative to mefloquine at the efficacious
dose is probably the minimum requirement. In this
study we have shown that at least a ten-fold reduction
in both parameters is feasible through replacement of
the piperidine ring of mefloquine with various other
four-position substituents. The prospect of such a com-
pound being better tolerated than mefloquine is, there-
fore, a possibility.
While a reduction in maximum brain concentration
should reduce the incidence of CNS associated adverse
events, optimizing this property alone will not be suffi-
cient for a new quinoline methanol anti-malarial. The
putative late lead compound must also have a
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Figure 2 Maximum whole (A) and free (B) brain concentrations
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Figure 3 Relationships amongst four important pharmacological parameters for quinoline methanols were evaluated for evidence of
correlations. A possible linear correlation between maximum and free brain concentration is evident on visual inspection of the data, and was
confirmed mathematically (r
2 = 0.89, P < 0.0001). There was no relationship evident between the other variables. Data are presented in a log
format for ease of visualization. The correlation coefficient was calculated based on raw (not log transformed) data.
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Page 7 of 11sufficiently long half-life and intrinsic efficacy to be use-
ful if administered as a single dose. Therefore, the goal
is to balance these three potentially competing pharma-
cological properties in the same molecule. There is an
opportunity to evaluate a subset of the larger 4-position
library using surrogates of these endpoints. Maximum
free and whole brain concentrations represent surro-
gates of CNS safety if they are sufficiently reduced rela-
tive to mefloquine at the therapeutic dose. Whilst the
plasma concentration-time data generated are insuffi-
cient to calculate pharmacokinetic parameters directly
in most instances, the proportion of drug remaining at
24 h relative to the 5 minute time point is probably a
reasonable surrogate of half-life, or at least persistence
in plasma. In vitro activity (IC90) can be utilized as a
surrogate for intrinsic activity.
There are no compounds amongst this sub-library that
meet all the requirements in terms of potency, low brain
levels and residual plasma concentrations at 24 h (see
Additional file 1) suggesting that further optimization is
required. The ideal chemotype around which to anchor
a future lead optimization program would be one in
which a balance between all these three properties is
achievable. The most active compounds were generally
those with aliphatic, ether or thio ether side chains
(WR308245, WR308246, WR308257, WR308265,
WR177000, WR308387, WR308278 and WR308412).
However, these compounds exhibited much higher brain
concentrations (free and whole) than mefloquine, and in
most instances, 24 h residual plasma concentrations
were < 1% of those at 5 min, indicating a likely short
half-life relative to mefloquine. The exception to this
general trend was the diamine WR308396. As might be
expected, all compounds with lower whole and free
brain concentrations than mefloquine had a greater
number of H-bond donors and/or acceptors than meflo-
quine. These compounds comprised a diverse array of
structures including alcohols, acids, triazines, substituted
cyclic imidazoles and diamines. However, with the
exceptions of the diamines WR319581 and WR318746,
these compounds exhibited a lack of potency (IC90 >
300 ng/ml) or low residual plasma concentrations (< 1%
at 24 h versus 5 min). Of the 25 compounds that were
not mefloquine or its enantiomers, only nine had resi-
dual plasma concentrations > 1% at 24 h, and five of
these were diamines. Consequently, a balance between
these properties may be most likely obtained amongst
diamine quinoline methanols.
Identifying a new lead compound with the requisite
balance of potency, brain partitioning and half-life might
not be feasible if it was true that positive trends in these
characteristics were mutually exclusive, however this
does not appear to be the case. Maximum free brain
concentrations, IC90s, and residual plasma concentra-
tions amongst quinoline methanols did not appear to be
correlated (Figure 3A-C). Therefore, at the outset there
is no reason to suspect that a balance between these
properties is not achievab l ei nad i a m i n eq u i n o l i n e
methanol. There are no generic algorithms that can be
used to objectively judge the probability of success of a
specific lead optimization programme a priori. Thus one
must extrapolate on a project-by-project basis with the
available data. The lack of a general correlation between
maximum free brain concentrations, residual plasma
concentrations and IC90s suggests that their probability
distributions may be independent. Thus, we estimated
the probability of a diamine quinoline methanol posses-
sing all these properties to be around 4%. This value
was obtained by multiplying the marginal probabilities
of success for the individual parameters of interest (Fig-
ure 5). The confidence intervals are wide (0-21%) which
is not surprising given the small sample sizes.
The probability estimate discussed above was based on
free brain concentrations being representative of CNS
exposure. We have not made the same calculations for
maximum whole brain concentrations, because the
assumption of independence between this variable and
I C 9 0m a ya r g u a b l yb el e s sj u s t i f i a b l e .H o w e v e r ,t w o
lines of evidence support the notion that a compound
with an acceptable maximum free brain concentrations
will also have an acceptable maximum whole brain con-
centrations. First, whole and free brain concentrations
in the broader group of quinoline methanols were
strongly correlated. This suggests that they are also not
independent, or put another way, that there is a strong
conditional probability whole brain concentrations will
be lower than mefloquine if this is the case for free
brain concentrations. Second, in the same broader
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Figure 4 Brain and plasma concentrations of racemic mefloquine
and the diamine WR319581 after IV dosing (5 mg/kg) to male
FVB mice.
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Page 8 of 11group of quinoline methanols it is also true that the
proportion of compounds exhibiting the desired whole
brain concentrations (28%) was higher than the propor-
tion of compounds exhibiting the desired free brain con-
centrations (8%). Additional studies are required to
determine whether these observations will hold for a lar-
ger sample of diamine quinoline methanols.
It is appropriate to execute a lead optimization pro-
gramme if it can be done with a reasonable probability
of success in a time frame of up to two years [20]. For
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HO
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IC90 W2 = 10
Whole Brain Cmax = 1807
Free Brain Cmax = 4.9
2 4 h%Re m a i n i n g=3 5
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HN
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F r e eB r a i nC m a x=3 . 8
24h % Remaining =2.4
WR308396
IC90 W2 = 6
Whole Brain Cmax = 1768
Fr e eB r a i nC m a x=3 . 5
24h % Remaining =4.6
WR308781
IC90 W2 > 500
Whole Brain Cmax = 689
Free Brain Cmax = 5.6
24h % Remaining =3.3
WR318744
IC90 W2 = > 500
Whole Brain Cmax = 593
F r e eB r a i nC m a x=3 . 5
24h % Remaining =1 7
WR319535/581
IC90 W2 = 275
Whole Brain Cmax = 145
Free Brain Cmax = 0.45
24h % Remaining =2.7
Figure 5 Structures, IC90s, maximum whole and free brain concentrations, and residual 24 h plasma concentrations of diamine
quinoline methanols. IC90s are expressed in ng/ml against the mefloquine-sensitive W2 strain of P. falciparum. Maximum whole and free brain
concentrations in male FVB mice after iv dosing (5 mg/kg) are expressed in ng/g. Residual plasma concentrations at 24 h after iv dosing are
expressed as a percentage relative to the 5 minute time point. One in 5 diamines (20%, WR308396) had acceptable potency. One in 5 diamines
had acceptable whole (20%, WR319535) and free (20%, WR319535) brain levels relative to mefloquine. WR319535 exhibited a half-life longer than
mefloquine after oral dosing (data not shown). For this reason we have assumed that the residual plasma concentrations at 24 h of all (100%) of
the diamines may be indicative of long half-lives.
Table 2 Utility of MDCK permeability screen for ranking maximum brain concentrations of quinoline methanols
relative to mefloquine.*
Compounds with Papp < 7.4 × 10
-6
cm/s
Compounds with Papp > 7.4 × 10
-6
cm/s
Compounds with lower maximum brain concentrations than
mefloquine
10 4
Compounds with higher maximum brain concentrations than
mefloquine
01 0
* Racemic mefloquine and isomers excluded
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Page 9 of 11planning purposes, it has been assumed the true prob-
ability of success for an individual compound lies some-
where between the lower confidence interval and 4%.
Since the synthetic route is amenable to the synthesis of
100 new compounds in 12-18 months, it is anticipated
that up to four potential late lead molecules will be
identified in that time frame. The assumed low probabil-
ity of success with any individual compound requires an
aggressive method of early triage. The permeability of a
compound across MDCK cell monolayers appears to
correctly categorize it relative to mefloquine in terms of
its maximum brain concentration in most instances. It
is, therefore, reasonable to use this assay together with
more routine P. falciparum susceptibility assays to
rapidly prioritize compounds for in vivo studies. It may
be necessary to conduct in vivo studies on a selection of
active, but permeable compounds triaged using this
technique in order to control the type II error rate. A
lead optimization campaign conducted broadly along
these lines is now underway.
Additional material
Additional File 1: Structures, physiochemical properties and
biological data for a collection of diamine quinoline methanols. This
file contains the structures of 25 diamine quinoline methanols, racemic
mefloquine and its isomers, their key physiochemical properties, and
biological data from Pf in vitro screening, cytotoxicity screening, MDCK
permeability studies, plasma and brain binding experiments, and brain
and plasma concentration data after i.v. dosing in mice. The methods are
described in the text of the manuscript.
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